Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Enhancing the expression and function of an EBV-TCR on engineeredT cells by combining Sc-TCR design with CRISPR editingto prevent mispairing

Enhancing the expression and function of an EBV-TCR on engineeredT cells by combining Sc-TCR... Cellular & Molecular Immunology www.nature.com/cmi CORRESPONDENCE Enhancing the expression and function of an EBV-TCR on engineered T cells by combining Sc-TCR design with CRISPR editing to prevent mispairing 1,2 1,2 3 2 1 1 1 1 Shao-An Xue , Yuan Chen , Ralf-Holger Voss , Virad Kisan , Bo Wang , Ke-Ke Chen , Feng-Qin He , Xiao-Xia Cheng , 2 2 2 2 2 Laura Scolamiero , Angelika Holler , Liquan Gao , Emma Morris and Hans J. Stauss Cellular & Molecular Immunology (2020) 17:1275–1277; https://doi.org/10.1038/s41423-020-0396-9 Adoptive transfer of antigen-specific T cells is an effective form of mCβ, while only 30.7% of these cells stained positive with the EBV- 1 + immunotherapy for cancers, and genetic modification of T cells pentamer. However, the percentage of mCβ cells rose moder- provides a rapid way to produce the desired tumor specificity ately to 82.4 and 94.5% in the EBV-Sc-TCR-CD19- and EBV-SSc-TCR- 3 4 + with improved T-cell survival and functions. Recent clinical trials CD19-transduced cells, and the percentage of EBV-pentamer have further demonstrated that TCR-engineered T cells can persist cells markedly increased to 63.1 and 84.9%, respectively. These and mediate clinical benefits in late-stage cancer patients. findings demonstrated dramatic improvements http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cellular & Molecular Immunology Springer Journals

Enhancing the expression and function of an EBV-TCR on engineeredT cells by combining Sc-TCR design with CRISPR editingto prevent mispairing

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/enhancing-the-expression-and-function-of-an-ebv-tcr-on-engineeredt-6iT2bcuxqt

References (10)

Publisher
Springer Journals
Copyright
Copyright © CSI and USTC 2020
ISSN
1672-7681
eISSN
2042-0226
DOI
10.1038/s41423-020-0396-9
Publisher site
See Article on Publisher Site

Abstract

Cellular & Molecular Immunology www.nature.com/cmi CORRESPONDENCE Enhancing the expression and function of an EBV-TCR on engineered T cells by combining Sc-TCR design with CRISPR editing to prevent mispairing 1,2 1,2 3 2 1 1 1 1 Shao-An Xue , Yuan Chen , Ralf-Holger Voss , Virad Kisan , Bo Wang , Ke-Ke Chen , Feng-Qin He , Xiao-Xia Cheng , 2 2 2 2 2 Laura Scolamiero , Angelika Holler , Liquan Gao , Emma Morris and Hans J. Stauss Cellular & Molecular Immunology (2020) 17:1275–1277; https://doi.org/10.1038/s41423-020-0396-9 Adoptive transfer of antigen-specific T cells is an effective form of mCβ, while only 30.7% of these cells stained positive with the EBV- 1 + immunotherapy for cancers, and genetic modification of T cells pentamer. However, the percentage of mCβ cells rose moder- provides a rapid way to produce the desired tumor specificity ately to 82.4 and 94.5% in the EBV-Sc-TCR-CD19- and EBV-SSc-TCR- 3 4 + with improved T-cell survival and functions. Recent clinical trials CD19-transduced cells, and the percentage of EBV-pentamer have further demonstrated that TCR-engineered T cells can persist cells markedly increased to 63.1 and 84.9%, respectively. These and mediate clinical benefits in late-stage cancer patients. findings demonstrated dramatic improvements

Journal

Cellular & Molecular Immunology – Springer Journals

Published: Mar 17, 2020

There are no references for this article.